MO-U.S.-SOYBEAN-EXPORT
6.7.2020 16:19:08 CEST | Business Wire | Press release
A new meta-analytical study reinforces U.S. Soy’s reputation for being a global leader in quality and nutrient-density. The study, entitled, “Chemical composition, protein quality and nutritive value of commercial soybean meals produced from beans from different countries,” demonstrates that not all soybean meals are created equal and that meal from different countries of origin should be treated individually when formulating swine and poultry diets. The data from this study were then processed by the Nutrient Value Calculator (NVC), a software tool constructed by Genesis Feed Technologies, a company built to bring visibility into feed costs. This cost analysis supported the economic benefits of U.S. soybean meal relative to meal from other origins as a key ingredient in poultry rations.
Dr. Gonzalo Mateos, Professor of Animal Science at the University of Madrid in Spain and study co-author, first presented findings from the meta-analysis at the U.S. Soybean Export Council’s (USSEC) Asia Trade Exchange to 850 U.S. Soy customers and soybean industry representatives. This pioneering compilation of research is the most comprehensive quality review of soybean meal that has ever been conducted, and it gives customers greater clarity around soybean meal quality from different countries of origin. The meta-analysis looked at 18 different studies and 1,944 samples to quantify the relationship between country of origin of the bean and the chemical composition and nutritive value of the soybean meal. Soybeans from the following origins were analyzed: Argentina (ARG), Brazil (BRA), USA (USA) and India (IND).
“One of the main points from the study, is that customers should be using different matrices for the evaluation of the nutritional value of soybean meals of different origins,” said Dr. Gonzalo Mateos, Professor of Animal Science at the University of Madrid, Spain . “If they buy only based on protein or vegetable sucrose content, they may buy a product that is actually lower quality. Therefore, it is important to check all of the values that are related to the nutritive value of the soybean meal before making purchase decisions, which this study addresses.”
The data in this meta-analysis forms a new key pillar of the economic evaluation of soybean meal in global markets. Using the Nutrient Value Calculator from Genesis Feed Technologies , the economic value of U.S. soybean meal can be evaluated in global markets using formulas representative of the regional feed manufacturers. Nutrient values and prices of all the other components of the diet are also used in this calculation. The NVC indicates that U.S. soybean meal is the leading contributor to cost reduction in broiler diets.
“Our company was thrilled to participate in this groundbreaking research conducted by the U.S. Soybean Export Council,” said Peter Schott, CEO and Co-Founder of Genesis Feed Technologies . “We hope that buyers take note of the results, purchase more U.S. soy and see a significant reduction in their feed costs. This NVC analyzes economic nutritional value of soybean meals from different origins to give traders and buyers a platform to connect with nutritionists directly to better inform their feed investments.”
When comparing cost reductions with incorporation of data from the aforementioned meta-analytical study, premiums of U.S. soybean meal range from $14.57 to $23.24 per tonne over Argentine soybean meal and range from $2.48 to $10.26 per tonne over Brazilian soybean meal.
“U.S. soy and soybean meal products offer a price advantage and rank first on a number of important nutritional attributes when compared to other origins, including remarkable amino acid and energy profiles,” said Paul Burke, USSEC’s Senior Director for U.S. Soy Marketing . “This will continue to ensure we deliver a valuable, consistent and more economical product that our customers can count on.”
Soybean meal is an important source of protein for the global feed industry, where it is used in livestock, poultry and aquaculture diets. To meet this demand for animal feed, the farmers that grow sustainable U.S. soy not only care about being a reliable supplier but take pride in providing a high-quality product to their international customers.
“The world’s need for a high-quality protein product like U.S. soybean meal will be critical as our population continues to grow. And U.S. farmers around the country are ready and willing to meet that need,” said Monte Peterson, Chairman of USSEC , board member of the American Soybean Association and soybean farmer in Valley City, N.D. “Our soybean farmers provide a consistent, nutritious and efficient source of protein for both the food and feed sectors. This meta-analysis is important because it shows how U.S. soy is the most high-quality and best economic choice, backed by science.”
To learn more and access a summary of the meta-analysis, click here . And register to watch USSEC’s recorded webinar with Dr. Gonzalo Mateos and Genesis Feed Technologies to hear key insights about the meta-analysis and better understand the nutritional value of U.S. soybean meal as compared to different origins.
ABOUT U.S. SOYBEAN EXPORT COUNCIL
The U.S. Soybean Export Council (USSEC) is a dynamic partnership of U.S. soybean producers, processors, commodity shippers, merchandisers, allied agribusinesses and agricultural organizations working to build preference for U.S. soy throughout the world. Through a global network of international offices and strong support in the U.S., USSEC works to build a preference for U.S. soybeans and soybean products, advocates for the use of soy in feed, aquaculture and human consumption, promotes the benefits of soy use through education, and connects industry leaders through a robust membership program. USSEC is partially funded by the United Soybean Board. Learn more at www.ussec.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
